Dr. Mahija Sahu,
BACKGROUND Poly Cystic Ovary Syndrome (PCOS) is a heterogeneous disorder, characterized by chronic anovulation and hyperandrogenism, which affects between 5 to 10% of women in reproductive age, and it is considered one of the most common endocrine disorders in premenopausal women The objective of this study was to evaluate the effects of 6 months of administration of Oral Contraceptive Pill (OCP) alone or in combination with metformin on clinical, hormonal, metabolic and ultrasonographic characteristics in polycystic ovarian syndrome (PCOS). MATERIALS AND METHODS One hundred and thirty PCOS patients were enrolled in this prospective single blind randomized control trial. PCOS was defined according to the Rotterdam criteria. Patients were randomized to either oral treatment with OCP containing ethinyl estradiol-cyproterone acetate alone (n = 66) or OCP in combination with metformin (n = 64). Body Mass Index (BMI), waist circumference (WC), Ferriman–Gallwey (FG) score, luteinizing hormone (LH), total testosterone (TT), lipid levels, fasting insulin, fasting glucose and ultrasonographic parameters such as ovarian volume (OV), follicle number (FN) and ovarian stromal pulsatility index (PI) and resistive index (RI) were measured at baseline and at the end of treatment.
